Douglas A. I. Pippin
B.Sc. degree in Chemistry from Central Connecticut State University in 1996 and Ph.D. in Synthetic Organic Chemistry in 2001 from Dartmouth College under the guidance of Professor Peter A. Jacobi. In 2002, he joined CGI Pharmaceuticals as a senior research scientist where he led high-throughput medicinal chemistry efforts in early lead identification and lead optimization of targeted kinase programs in oncology and autoimmune/anti-inflammatory disease. In 2005, Dr. Pippin joined Cephalon, Inc. where he continued his work in the investigation of agents for treatment of cellular proliferation and CNS disorders. In 2009, he founded TransSig, Inc.; as its President and CEO, Pippin continues to focus on the discovery, development and marketing of novel multi-target signal transduction modulating agents for the treatment of cellular proliferation disorders in unmet clinical needs. In 2011, he co-founded PuriSpec, LLC, a company focused on the spectrographic analysis and purification of diverse sets of compounds for numerous applications in drug discovery, with the use of supercritical fluid chromatography/mass spectrometry (SFC/MS). Dr. Pippin currently sits on the board of three privately-held biotechnology firms, TransSig, Inc., PuriSpec, LLC, and Theraceutix, LLC. He is an inventor on 32 patents (issued/pending) and an author of 16 scientific publications and review articles.